Objective To analyze nosocomial infection related factors among respiratory department patients and discuss corresponding nursing measures. Methods Clinical data of 2142 patients with respiratory disease were analyzed retrospectively, the nosocomial infection associated risk factors were analyzed. Results 138 cases (6.4%)in 2142 patients suffered nosocomial infection, the related risk factors included age, the length of hospitalization time, whether having aggressive treatment or basic diseases of other system, whether used broad- spectrum antibiotics or chemotherapy drugs or hormone, etc. Conclusions Positive and effective treatment of primary disease, disinfection and isolation of ward, cutting off infection pathway, doing basic job, and keeping respiratory tract smooth were effective measures to reduce nosocomial infection.

Objective To analyze the ultrasound findings of urinary calculi caused by melamine. Methods The urinary system of totally 5337 children were examined with high frequency convex ultrasound probe,the characteristics of the images were analysed. CT plain scan method was used when ultrasound result was in difficulty. Results There were 360 cases with calculus in the 5337 children. In the 360 cases, unilateral calculus was in 92 cases, bilateral calculus in 48, bladder stone in 3, urethra stone in 1, kidney calcium deposition in 2, suspicion stone in 214 cases, urinary obstruction in 28 of them. The size of the stones ranged from 3 mm×2 mm to stag-horn calculus. Conclusions The urinary calculi caused by melamine is sandy stone. Ultrasound result is equivocal in the disease, CT plain scan can be a method of choice. High frequency convex probe provides more clear images, more evident adminstrative levels of anatomise than general abdominal probe does. It is beneficial for diagnosing and differential diagnosing of these diseases.

Objective:To compare the efficacy and safety of Tonghua Dongbao′s insulin aspart injection (Rishulin) and NovoRapid (Novo Nordisk) in the treatment of diabetes.Methods:A 26-week, randomized, open-label, parallel-group, positive control drug and non-inferiority trial was conducted in 23 centers in China. A total of 563 diabetes with poor blood glucose control treated with insulin for at least 3 months before were included. The subjects were randomized(stratified block random method) into those receiving Rishulin or NovoRapid at a ratio of 3∶1. Both groups were combined with basal insulin (Lantus). The primary endpoint was the change in glycosylated hemoglobin (HbA1c) from baseline to the end of 24 weeks of treatment.Results:For full analysis set, after 24 weeks of treatment, HbA1c level of Ruishulin group decreased from (8.66±1.28)% to (7.77±1.09)% ( P<0.001), and that of NovoRapid group decreased from (8.47±1.28) % to (7.65±0.97) % ( P<0.001). Treatment difference in HbA1c (NovoRapid group-Ruishulin group) was -0.061% (95% CI -0.320-0.199). HbA1c<7.0% target reacing rates were 24.26% and 21.21% ( P=0.456), and HbA1c<6.5% target reacing rates were 9.65% and 6.82% ( P=0.310) in Ruishulin group and NovoRapid group, repectively. The standard 2 hours postprandial blood glucose (2hPG) in Ruishulin group decreased from (16.23±5.22) mmol/L to (12.65±4.57) mmol/L ( P<0.001), and 2hPG in NovoRapid group decreased from (16.13±5.37) mmol/L to (11.91)±4.21) mmol/L ( P<0.001). The fingertips blood glucose at 7-point of both groups exhibited varying degrees of reduction compared with those at baseline, repectively. Positive ratios of specific antibodies were 31.68% in Ruishulin group and 36.36% in NovoRapid group ( P=0.320). Ratios of negative to positive were 7.43% and 10.61% ( P=0.360), and ratios of positive to negative were 10.40% and 7.58% ( P=0.360) in Ruishulin group and NovoRapid group, respectively. The incidence of hypoglycemia was 60.05% and 55.40% ( P=0.371), and the incidence of adverse events was 76.60% and 77.70% ( P=0.818) in Ruishulin group and NovoRapid group, respectively. Conclusions:Rishulin is not inferior to NovoRapid, and has shown good efficacy and safety. It can be an ideal choice for clinicians in patients with poor blood glucose control with insulin.